

# Leukaemia and Lymphoma Treatment

---

Reference Number: F4632  
Date of Response: 16<sup>th</sup> May 2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

## **Royal Devon's Eastern FOI Office Response**

Q1. How many patients has your trust treated in the past 3 months for the following conditions:

- Chronic Lymphocytic Leukaemia (CLL): **53 Patients**
- Mantle Cell Lymphoma (MCL): **10 Patients**
- In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to: **Not applicable.**

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

- BR (bendamustine + rituximab): **0 Patients**
- Calquence (acalabrutinib): **0 Patients**
- Gazyva (obinutuzumab) + chlorambucil: **0 Patients**
- Imbruvica (ibrutinib): **18 Patients**
- Venclexta (venetoclax): **17 Patients**
- Venclexta (venetoclax) + Gazyva (obinutuzumab): **0 Patients**
- Zydelig (idelalisib) + rituximab: **0 Patients**
- Any other systemic anti-cancer therapy: **15 Patients**

**In accordance with section 40 (2) of the Freedom of Information Act 2000, We are unable to provide the figures for the following treatments:**

- **FCR (fludarabine + cyclophosphamide + rituximab)**
- **Venclexta (venetoclax) + rituximab**

**We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above products is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and all principles of the Data Protection Act 1998.**

Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:

- BR (bendamustine + rituximab): **0 Patients**
- R-BAC (rituximab, bendamustine and cytarabine): **0 Patients**
- R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone): **0 Patients**
- Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone): **0 Patients**
- Velcade (bortezomib) + chemotherapy: **0 Patients**
- Stem Cell Transplant: **0 Patients**
- Tecartus (CART-T) – Autologous anti-CD19-transduced CD3+cells: **0 Patients**

**In accordance with section 40 (2) of the Freedom of Information Act 2000, We are unable to provide the figures for the following treatments:**

- **Imbruvica (ibrutinib)**
- **Imbruvica (ibrutinib) + rituximab**
- **Any other systemic anti-cancer therapy**

**We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above products is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and all principles of the Data Protection Act 1998.**

Q4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?

**The Trust currently participates in the Flair trial. 17 Patients have been recruited to this.**

Q5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

**The Trust currently participates in the Enrich trial. Although the Trust holds the data relating to how many patients are currently recruited on this trial, under section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients recruited is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and all principles of the Data Protection Act 1998.**

**Section 40(2) of the FOIA states that information is exempt from disclosure if it constitutes the personal data of a third party and its**

disclosure under the FOIA would breach any of the data protection principles or section 10 of the Data Protection Act 1998

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.